



# JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
 Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181  
 Unaudited Financial Results for the Quarter / Half year ended 30.09.2015

Particulars	Rs. in lacs					
	3 months ended 30.09.2015 Unaudited	3 months ended 30.06.2015 Unaudited	3 months ended 30.09.2014 Unaudited	6 Months ended 30.09.2015 Unaudited	6 Months ended 30.09.2014 Unaudited	12 Months Ended 31.03.2015 Audited
<b>1 Income from operations</b>						
a Net sales/income from Operations (Net of excise duty)	3296.86	3696.85	3296.06	6995.71	6687.37	13815.09
b Other Operating Income	30.94	0.00	0.00	30.94	0.00	0.00
<b>Total Income from operations (net)</b>	<b>3327.80</b>	<b>3696.85</b>	<b>3296.06</b>	<b>7026.65</b>	<b>6687.37</b>	<b>13815.09</b>
<b>2 Expenses</b>						
a Cost of materials consumed	2164.71	1310.02	1993.77	3474.73	2855.39	6383.36
b Purchases of stock-in-trade	287.62	117.40	347.08	385.02	556.71	649.48
c Changes in inventories of finished goods, work in progress	-1147.36	507.09	-859.78	-640.27	-394.94	-164.55
d Employee benefits expenses	967.46	823.60	754.60	1791.05	1649.58	3211.33
e Depreciation and amortisation expense	73.08	69.14	71.81	142.22	142.90	270.69
f Other expenses	825.27	687.92	813.35	1513.19	1484.02	2862.86
<b>Total expenses</b>	<b>3150.78</b>	<b>3515.17</b>	<b>3120.83</b>	<b>6885.95</b>	<b>6293.66</b>	<b>15213.17</b>
<b>3 Profit from Operations before Other Income, Finance Cost and Exceptional Items (1-2)</b>	<b>177.02</b>	<b>183.68</b>	<b>175.23</b>	<b>360.70</b>	<b>393.71</b>	<b>601.92</b>
<b>4 Other Income</b>	<b>3.41</b>	<b>2.90</b>	<b>2.03</b>	<b>6.31</b>	<b>5.14</b>	<b>11.10</b>
<b>5 Profit from ordinary activities before finance cost and Exceptional items (3+4)</b>	<b>180.43</b>	<b>186.58</b>	<b>177.26</b>	<b>367.01</b>	<b>398.85</b>	<b>613.02</b>
<b>6 Finance Cost</b>	<b>120.68</b>	<b>123.33</b>	<b>107.54</b>	<b>244.01</b>	<b>228.15</b>	<b>445.85</b>
<b>7 Profit from ordinary activities after finance cost but before Exceptional Items (5-6)</b>	<b>59.75</b>	<b>63.25</b>	<b>69.72</b>	<b>123.00</b>	<b>170.70</b>	<b>167.17</b>
<b>8 Exceptional Items</b>						
<b>9 Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)</b>	<b>59.75</b>	<b>63.25</b>	<b>69.72</b>	<b>123.00</b>	<b>170.70</b>	<b>167.17</b>
<b>10 Tax expense</b>	<b>15.90</b>	<b>16.70</b>	<b>33.00</b>	<b>32.60</b>	<b>63.00</b>	<b>50.08</b>
<b>11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)</b>	<b>43.85</b>	<b>46.55</b>	<b>36.72</b>	<b>90.40</b>	<b>107.70</b>	<b>117.11</b>
<b>12 Extraordinary Items (net of tax expense Rs. lacs)</b>						
<b>13 Net Profit(+)/Loss(-) for the period(11-12)</b>	<b>43.85</b>	<b>46.55</b>	<b>36.72</b>	<b>90.40</b>	<b>107.70</b>	<b>117.11</b>
<b>14 Share of profit/(Loss) of associates</b>						
<b>15 Minority interest</b>						
<b>16 Net Profit/(Loss) after taxes, minority interest and share of</b>	<b>43.85</b>	<b>46.55</b>	<b>36.72</b>	<b>90.40</b>	<b>107.70</b>	<b>117.11</b>
<b>17 Paid up Eq. Sh. Cap. (Face value Rs. 5)</b>	<b>1309.90</b>	<b>1309.90</b>	<b>1309.90</b>	<b>1309.90</b>	<b>1309.90</b>	<b>1309.90</b>
<b>18 Reserves excluding Revaluation reserves as per Balance sheet of cr. Accounting vt</b>						<b>7448.74</b>
<b>19.i Earnings Per Share (before extraordinary items)</b>						
a. Basic (Rs.)	0.17	0.18	0.14	0.35	0.41	0.45
b. Diluted (Rs.)	0.17	0.18	0.14	0.35	0.41	0.45
<b>19.ii Earnings Per Share (after extraordinary items)</b>						
a. Basic (Rs.)	0.17	0.18	0.14	0.35	0.41	0.45
b. Diluted (Rs.)	0.17	0.18	0.14	0.35	0.41	0.45
<b>A PARTICULARS OF SHAREHOLDING</b>						
<b>1 Public Shareholding</b>						
- Number of shares	8076680	8076680	8076680	8076680	8076680	8076680
- Percentage of Shareholding	30.83%	30.83%	30.83%	30.83%	30.83%	30.83%
<b>2 Promoter and promoter group shareholding</b>						
<b>A Pledged / encumbered</b>						
- Number of shares						
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)						
- Percentage of shares (as a % of the total share capital of the Company)						
<b>B Non - encumbered</b>						
- Number of shares	18121320	18121320	18121320	18121320	18121320	18121320
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	69.17%	69.17%	69.17%	69.17%	69.17%	69.17%
<b>B INVESTOR COMPLAINTS</b>						
Pending at the beginning of the quarter	0					
Received during the quarter	25					
Disposed of during the quarter	25					
Remaining unresolved at the end of the quarter	0					

**Notes:**

- The Unaudited Financial Results for the Quarter / Half Year ended 30.9.2015 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 10.11.2015
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous year figures have been regrouped / rearranged wherever necessary.

By Order of the Board  
 For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar  
 Managing Director  
 DIN No 00059492



Place : New Delhi  
 Date : 10.11.2015

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953  
 Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

CIN No. L74899DL1978PLC009181

### Statement of Assets and Liabilities

		Rs. In lacs		Rs. In lacs			
A	EQUITY AND LIABILITIES	As at 30.09.2015 Unaudited	As at 30.09.2014 Audited	B	ASSETS	As at 30.09.2015 Unaudited	As at 30.09.2014 Audited
1	Shareholders' funds			1	Non-current assets		
	(a) Share Capital	1309.90	1309.90		(a) Fixed Assets	5196.14	5770.60
	(b) Reserves and surplus	8323.06	8656.57		(b) Goodwill	3.00	3.00
	Sub-total - Shareholders' funds	9632.96	9966.47		(c) Non-current investments	0.05	0.05
2	Share application money pending allotment	0.00	0.00		(d) Deferred tax assets (net)	0.00	0.00
3	Minority interest	0.00	0.00		(e) Long term loans and advance	652.62	633.52
4	Non-current liabilities				(f) Other non-current assets	0.00	0.00
	(a) Long term borrowings	0.00	0.00		Sub-total - Non-current assets	5851.81	6407.17
	(b) Deferred tax liabilities (net)	368.26	378.39	2	Current assets		
	(c) Other long term liabilities	0.00	0.00		(a) Current investments		
	(d) Long term provisions	0.00	0.00		(b) Inventories	3962.72	3460.02
	Sub-total - Non-current liabilities	368.26	378.39		(c) Trade receivables	4019.65	4511.04
5	Current liabilities				(d) Cash and Cash equivalents	1441.67	1265.09
	(a) Short term borrowing	3841.17	3593.76		(e) Short term loans and advance	286.11	311.00
	(b) Trade payables	841.17	703.11		(f) Other current assets	0.00	0.00
	(c) Other current liabilities	660.76	573.44		Sub-Total - Current assets	9710.15	9547.15
	(d) Short term provisions	217.64	739.15				
	Sub-Total - Current liabilities	5560.74	5609.46				
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>15561.96</b>	<b>15954.32</b>		<b>TOTAL - ASSETS</b>	<b>15561.96</b>	<b>15954.32</b>

for Jagsonpal Pharmaceuticals Limited

*Ravindra*  
Managing Director

**LIMITED REVIEW REPORT FOR**

The Board of Directors  
Jagsonpal Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the Quarter / Half year ended 30.09.2015, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by Audit Committee and Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, engagements to "Review of Interim Financial Information Performed Independent Auditor of the entity" by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Accounting Standards specified under Section 133 of the Companies Act 2013, read with rule 7 of the Companies (Accounts) rule, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. P. THUKRAL & CO.,  
Chartered Accountants

Place : New Delhi  
Date : 10.11.2015



  
SURESH SETHI  
PARTNER  
F.R. No. 000632 N  
Membership no. 89318